Ind-Swift Labs launches anti-allergic drug Fexofenadine in US
Fexofenadine is an AntiHistamine Drug used for the treatment of seasonal allergic rhinitis and Urticaria in US market.
Advertisement
Chandigarh: Ind-Swift Laboratories Limited has recently announced that the Company is all set to commercially launch its key Active Pharmaceutical Ingredient (API) - Fexofenadine.
Fexofenadine is an AntiHistamine Drug used for the treatment of seasonal allergic rhinitis and Urticaria in US market.
The Company has tied up with a reputed generic player in the USA, which had filed the ANDA using the IndSwift Laboratories Limited DMF. The Company has received the commercial orders and the supplies are beginning from the current quarter.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.